• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
Nairametrics
Home Sectors Health

NAFDAC alerts Nigerians to falsified Dostinex tablets in circulation

Rosalia Ozibo by Rosalia Ozibo
February 24, 2026
in Health, Sectors
NAFDAC orders ban of sachet alcohol and bottles below 200ml from December 2025 
Share on FacebookShare on TwitterShare on Linkedin

The National Agency for Food and Drug Administration and Control has warned healthcare providers, patients, and the public about falsified versions of Dostinex 0.5mg tablets circulating in Nigeria.

This alert was issued in a public notice by the agency following confirmation from Pfizer Nigeria Ltd, the product’s marketing authorization holder.

The warning comes amid concerns that unregistered and parallel-imported medicines pose serious public health risks.

MoreStories

AAM2025: Tinubu calls for PAPSS payment system embracement across Africa for financial integration 

Tinubu orders deployment of 100,000 CNG conversion kits nationwide

March 11, 2026
Middle East tension: British Airways suspends flights to Abu Dhabi

Middle East tension: British Airways suspends flights to Abu Dhabi

March 10, 2026

What NAFDAC said 

According to NAFDAC, falsified and parallel unregistered versions of Dostinex 0.5mg tablets have been identified in circulation, even though the legitimately registered product has not yet been imported into Nigeria.

  • “Pfizer Nigeria Ltd, the Marketing Authorization Holder (MAH) of the products, has confirmed the presence of falsified and parallel unregistered imported versions of these products. According to Pfizer Nigeria Ltd, the legitimate product has been registered but has not yet been imported into Nigeria. 
  • “Dostinex 0.5 mg is a medication that reduces prolactin secretion, helping to alleviate symptoms caused by excess prolactin,” they said

The product details are: 

  • Batch numbers: GG3470, LG8659, GG2440
  • Expiry dates: June 2027, January 2026, April 2026
  • NAFDAC registration number: None
  • Manufacturer: Pfizer Italia S.R.L., Ascoli Piceno, Italy

NAFDAC stated that falsified, unlicensed, or unregistered medicines have not been evaluated by the agency, meaning their quality, safety, and effectiveness cannot be guaranteed.

More insights 

All zonal directors and state coordinators have been directed to carry out surveillance and remove the unregistered products wherever found.

Distributors, retailers, healthcare professionals, and caregivers are advised to exercise vigilance and ensure medicines are sourced only from authorized and licensed suppliers. Healthcare facilities are urged to review existing stock and report suspected falsified or compromised products to the nearest NAFDAC office.

Patients are also encouraged to report adverse reactions or side effects through NAFDAC offices, the agency’s e-reporting platforms, or the Med-safety mobile application. The agency said an alert will be uploaded to the World Health Organization Global Surveillance and Monitoring System to support international tracking of falsified medical products.

What you should know 

The National Agency for Food and Drug Administration and Control has repeatedly warned that falsified, tampered, and unregistered health products pose serious risks to public safety.

In a recent safety alert, the agency flagged a suspected revalidated SMA Gold infant formula discovered in Kaduna State after altered expiry dates were linked to illness in a four-month-old infant.

  • In one major operation in Lagos, NAFDAC intercepted counterfeit malaria medicines valued at over N1.2 billion hidden in a warehouse, with the fake drugs illegally imported and disguised as other goods before being seized by agency operatives.
  • NAFDAC has also destroyed unwholesome and expired medical products valued at more than N15 billion in Ibadan, removing falsified and harmful drugs from circulation to protect public health.

Add Nairametrics on Google News
Follow us for Breaking News and Market Intelligence.
Rosalia Ozibo

Rosalia Ozibo

Rosalia is a versatile journalist with a focus on technology and education. She has a talent for turning complex ideas into engaging stories, exploring how innovation and learning shape the future of people, business, and society. From tracking shifts in digital transformation and emerging tech to writing about developments in education policy and practice, her work bridges insight and accessibility. Known for sharp analysis and compelling storytelling, she continues to provide readers with perspectives that connect knowledge, opportunity, and the evolving world of work.

Next Post
EFCC: Achimugu’s case unrelated to Atiku, Sanwo-Olu, agency says

EFCC arraigns ex-NRC MD over alleged $385,000 money laundering

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

rabafast
rabafast

nairametrics





DUNS

Follow us on social media:

  • HOME
  • ABOUT NAIRAMETRICS
  • CONTACT US
  • DISCLAIMER
  • ADs DISCLAIMER
  • COPYRIGHT INFRINGEMENT

© 2026 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Login
  • Sign Up

© 2026 Nairametrics